+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Immuno-Oncology Diagnostics: The Race for Biomarkers - Market Forecasts for Immuno-Oncology Diagnostics - With Executive and Consultant Guides and including Customized Forecasting and Analysis (2019 to 2023)

  • ID: 4756906
  • Report
  • Region: Global
  • 216 Pages
  • Howe Sound Research
1 of 4
Nobel Prize Signals Move of Immuno-Oncology to a Frontline Role. Diagnostics to Play a Leading Role in Treatment Selection.

FEATURED COMPANIES

  • 10X Genomics
  • Biodesix Inc.
  • CytoTrack
  • Guardant Health
  • Merck & Co., Inc
  • Promega
  • MORE

Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

A revolution in cancer therapy is underway. New therapy based on using the body’s natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 10X Genomics
  • Biodesix Inc.
  • CytoTrack
  • Guardant Health
  • Merck & Co., Inc
  • Promega
  • MORE

i. Market Guides
iA. Situation Analysis 
iB. Guide for Executives and Marketing Staff 
iC. Guide for Investment Analysts and Management Consultants 
iD. Impact of the Nobel Prize

1. Introduction and Market Definition
1.1 What are Immuno-Oncology Diagnostics? 
1.2 Immuno-oncology – the looming cure.
1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
1.3 Market Definition
1.3.1 Market Size 
1.3.2 Currency 
1.3.3 Years 
1.4 Methodology 
1.4.1 Authors 
1.4.2 Sources 
1.5 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Immunotherapy – Guide to Immune Technologies
2.0 The Immune System 
2.0.1 Innate immune system 
2.0.1.1 Surface barriers 
2.0.1.2 Inflammation 
2.0.1.3 Complement system
2.0.1.4 Cellular barriers 
2.0.1.5 Natural killer cells
2.0.2 Adaptive immune system 
2.0.2.1 Lymphocytes
2.0.2.2 Killer T cells
2.0.2.3 Helper T cells 
2.0.2.4 Gamma delta T cells
2.0.2.5 B lymphocytes and antibodies
2.0.3 Tumor immunology – the immune surveillance system
2.1 Immuno OncologyDiagnostics
2.1.1 Checkpoint Assays
2.1.1.1 Outlook for Checkpoint Assays
2.1.2 Cytokine Assays
2.1.2.1 Outlook for Cytokine Assays
2.1.3 Genomic Germline 
2.1.3.1 Outlook for Genomic Germline 
2.1.4 Genomic Tumour
2.1.4.1 Outlook for Genomic Tumour 
2.1.5 Tumor Microenviroment
2.1.5.1 Outlook for Tumor Micro Environment
2.1.6 Others 
2.1.6.1 Outlook for Other Diagnostics 

3. Industry Overview 
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Genomic Instrumentation Supplier
3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
3.1.4 Pharmaceutical/Reagent Supplier
3.1.5 Independent Testing Lab
3.1.6 Public National/regional lab 
3.1.7 Hospital lab 
3.1.8 Physician Lab
3.1.9 Audit Body
3.1.10  Certification Body

4. Market Trends 
4.1 Factors Driving Growth 
4.1.1 Outcome potential 
4.1.2 Companion Diagnostics
4.1.3 Funding 
4.1.4 Technology Environment 
4.1.5 Target Solutions 
4.2 Factors Limiting Growth
4.2.1 Complex Role of Diagnostics
4.2.2 Clinical Trials Role 
4.2.3 Protocols
4.3 Diagnostic Technology Development 
4.3.1 Combinations - Issues and Complexity
4.3.2 Shifting Role of Diagnostics
4.3.3 Multiplexing and Foundation One 
4.3.4 The Disruption Dynamic 
4.3.5 The Race for Biomarkers
4.3.6 The Next Five Years

5. Cancer Immunotherapy Recent Developments
5.1 Recent Developments – Importance and How to Use This Section 
5.1.1 Importance of These Developments
5.1.2 How to Use This Section 
Icon Acquires MolecularMD 
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
Tumor Mutational Burden as Predictor of Immunotherapy Success 
Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda 
Cancer Genetics and NovellusDx to Merge
ApoCell Expands Immuno-Oncology Biomarker Services 
MRM Proteomics Inc and Exactis Innovation Partner
Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma
Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution 
MolecularMD Launches Validated Tumor Mutation Burden Assay 
Minomic Secures Key Patent in the United States and China
Biocartis and Wondfo Announce Joint Venture 
Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics 
Cancer Genetics Expands Immuno-Oncology Panel 
10x Genomics Acquires Epinomics, To Launch ATAC-Seq Product 
Qiagen, Freenome Partner to Improve Companion Diagnostic Development
Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime 
Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio 
Bristol-Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology Immunotherapies 
HalioDx announces high capacity IHC multiplex technology
MolecularMD to Implement Promega’s Technology
NCI, NanoString Collaborate to Evaluate Utility of PanCancer Gene Expression Panel 
MIODx to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy Response
Personal Genome Diagnostics Licenses Tumor Mutation Burden from MSKCC
HalioDx Closes €18.5M Series B Round
Announcement of the 2018 Nobel Prize in Physiology or Medicine

6.  Profiles of Key Immunotherapy Companies 
10X Genomics 
Abbott Laboratories
Adaptive Biotechnologies 
Aethlon Medical
Agena Bioscience
Angle plc
Apocell
ARUP Laboratories
Beckman Coulter 
Becton Dickinson
Bioarray Genetics
BioCartis
Biocept
Biodesix Inc.
BioFluidica 
BioGenex 
bioMérieux
Bio-Rad
Bio-Techne
Bristol-Myers Squibb 
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life 
Charles River 
Chronix Biomedical 
Circulogene 
Clearbridge BioMedics
Clinical Genomics
Cynvenio 
Cytolumina Technologies Corp.
CytoTrack
Dako (Agilent) 
Diagnologix LLC 
Epic Sciences 
Exosome Diagnostics
Fluidigm Corp
Fluxion Biosciences 
Foundation Medicine
Freenome
Genomic Health
GenomOncology
GRAIL 
Guardant Health 
HalioDx
Horizon Discovery 
HTG Molecular Diagnostics 
iCellate
Illumina 
Incell Dx 
Inivata 
Integrated Diagnostics
Invivoscribe 
Leica Biosystems 
Luminex 
MDx Health 
Merck & Co., Inc
MIODx 
Molecular MD 
MRM Proteomics Inc
Myriad Genetics/Myriad RBM
Nanostring 
Natera 
Neogenomics
New Oncology 
Oncocyte 
Ortho Clinical Diagnostics 
Perkin Elmer
Personal Genome Diagnostics
Pfizer 
Promega
Protagen Diagnostics
Qiagen 
Quanterix
Rarecells SAS 
Roche Diagnostics 
Siemens 
Silicon Biosystems 
SkylineDx 
SRI International 
Sysmex
Thermo Fisher 
Trovagene 
Vortex Biosciences

7. Global Market Size 
7.1 Immuno-oncology Diagnostics Global Market Size by Country with Charts
7.2 Immuno-oncology Diagnostics Global Market Size by Type with Charts 

8. Global Market by Type
8.1 Checkpoint Assay Market 
8.1.1 Checkpoint Assay Market by Country with Chart
8.2 Cytokine Assay Market 
8.2.1 Cytokine Assay Market by Country with Chart
8.3 Genome Germline Market
8.3.1 Genome Germline Market by Country with Chart 
8.4 Genome Tumour Market
8.4.1 Genome Tumour Market by Country with Chart 
8.5 Tumour Micro Environment Market 
8.5.1 Tumour Micro Environment Market by Country with Chart 
8.6 Other Market
8.6.1 Other Market by Country with Chart 

9. Appendices
9.1 FDA Cancer Drug Approvals by Year 
9.2 Clinical Trials Started 2010 to 2016
9.3 Prevalence of Cancer Treatments – 2015 

List of Tables
Table 1 List of Cancers by Mortality 
Table 2 Lab Spending 2014 to 2024 
Table 3  Overview of Innate and Adaptive Immunity 
Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment
Table 5 FDA Approved Companion diagnostics in Cancer treatment
Table 6  Market Players by Type 
Table 7 Five Factors Driving Growth 
Table 8 Three Factors Limiting Growth
Table 9 Immuno-oncology Diagnostics Global Market by Country/Region 
Table 10 Immuno-oncology Diagnostics Global Market by Type 
Table 11 Checkpoint Assay Market by Country
Table 12 Cytokine Assay Market by Country
Table 13 Genome Germline Market by Country
Table 14 Genome Tumour Market by Country
Table 15 Tumour Micro Environment Market by Country 
Table 16 Other Market by Country
 
List of Figures
Figure 1 Cancer Death Rates – USA, CDC 
Figure 2 Clinical Lab Spending 2014 to 2024
Figure 3 Helper T Cell Roles
Figure 4 Antibody Diagram 
Figure 5 Macrophages attack a Cancer Cell 
Figure 6 The Tumour Micro Environment
Figure 7 Comparing IO Diagnostic and Traditional Testing
Figure 8 Growth rates of IO DiagnosticTechnologies 
Figure 9 Market Size by Country - Key Countries 
Figure 10  Global Market by Country 
Figure 11 Chart of Global Market by Type 
Figure 12 Growth Rates of Diagnostic Segments 
Figure 13 IO Diagnostics Share Change by Type
Figure 14 Chart – Checkpoint Assay Market by Country
Figure 15 Chart – Cytokine Assay Market by Country
Figure 16 Chart – Genome Germline Market by Country
Figure 17 Chart - Genome Tumour Market by Country 
Figure 18 Chart – Tumour Micro Environment Market by Country 
Figure 19 Chart – Other Market, Global Size
Figure 20 FDA Cancer Drug Approvals by Year 
Figure 21 Clinical Trials for Immunotherapy by Year 
Figure 22 Pie Chart of Prevalence of Cancer Treatments

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 10X Genomics
  • ARUP Laboratories
  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Agilent Companion Diagnostic
  • Angle plc
  • ApoCell
  • AstraZeneca
  • Beckman Coulter
  • Becton Dickinson
  • Bio-Rad
  • Bio-Techne
  • BioCartis
  • BioFluidica
  • BioGenex
  • Bioarray Genetics
  • Biocartis
  • Biocept
  • Biodesix Inc.
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • CytoTrack
  • Cytolumina Technologies Corp.
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Epinomics
  • Exactis Innovation
  • Exosome Diagnostics
  • Five Prime Therapeutics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GRAIL
  • GenomOncology
  • Genomic Health
  • Guardant Health
  • HTG Molecular Diagnostics
  • HalioDx
  • Horizon Discovery
  • Icon
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Keytruda
  • Leica Biosystems
  • Luminex
  • MDx Health
  • MIODx
  • MRM Proteomics Inc
  • MSKCC
  • Merck & Co., Inc
  • Minomic
  • MolecularMD
  • Myriad Genetics/Myriad RBM
  • NCI
  • NanoString
  • Natera
  • Neogenomics
  • New Oncology
  • NovellusDx
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • SRI International
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences
  • Wondfo
  • bioMérieux
  • iCellate
Note: Product cover images may vary from those shown
Adroll
adroll